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Abstract
Background: One-month dual antiplatelet treatment, with aspirin and clopidogrel, following
internal carotid artery stent placement is the current standard of care to prevent in-stent
thrombosis. Cilostazol, an antiplatelet drug, has been demonstrated to have a safety profile
comparable to aspirin and clopidogrel. Objective: To evaluate the safety and clinical efficacy
of cilostazol and aspirin therapy following internal carotid artery stent placement up to 1
month postprocedure. Methods: A phase I open-label, nonrandomized two-center prospective study was conducted. All subjects received aspirin (325 mg/day) and cilostazol (200 mg/
day) 3 days before extracranial stent placement. Two antiplatelet agents were continued for
1 month postprocedure followed by aspirin daily monotherapy. The primary efficacy end
point was the 30-day composite occurrence of death, cerebral infarction, transient ischemic
attack, and in-stent thrombosis. The primary safety end point was bleeding. Results: Twelve
subjects (mean age ± SD, 66 ± 12 years; 9 males) were enrolled and underwent internal carotid artery angioplasty and stent placement. None of the subjects who successfully followed
the study protocol experienced any complications at the 1- and 3-month follow-ups. One patient had a protocol deviation due to concurrent use of enoxaparin (1 mg/kg twice daily) in
addition to aspirin and cilostazol, resulting in a fatal symptomatic intracerebral hemorrhage
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following successful stent placement on postprocedure day 1. One patient discontinued cilostazol after the first dose secondary to dizziness. Conclusion: The use of cilostazol and aspirin for internal carotid artery stent placement appears to be safe, but protocol compliance
needs to be emphasized.
© 2016 S. Karger AG, Basel

Introduction

Cilostazol, an antiplatelet medication different from aspirin and clopidogrel, selectively
inhibits phosphodiesterase III, increases intraplatelet intracellular cyclic 3′-5′-adenosine
monophosphate levels, activates protein kinase A, and decreases intracellular calcium levels
[1, 2]. The antiplatelet effect of cilostazol, a prodrug, begins after it is hepatically metabolized.
It has been demonstrated to have pleiotropic effects, reducing smooth muscle proliferation
and intimal hyperplasia and causing vasodilation [3–5]. Cilostazol, also known as Pletal, has
been approved in the United States since 1999 for the treatment of symptomatic peripheral
arterial disease [6]. The Cilostazol Stroke Prevention Study (CSP 2) demonstrated that cilostazol (200 mg/day) was associated with fewer incidence of hemorrhagic events compared
to aspirin (81 mg/day) for the prevention of stroke after an initial ischemic stroke (1.2 vs.
0.036%) with similar risk reduction for ischemic events [7].
The 2011 multispecialty Guidelines on the Management of Patients with Extracranial
Carotid and Vertebral Artery Disease: Executive Summary recommended dual antiplatelet
therapy with aspirin (81–325 mg daily) plus clopidogrel (75 mg daily) prior to and for a
minimum of 30 days after carotid artery stent placement; for patients intolerant of clopidogrel, ticlopidine (250 mg twice daily) may be substituted based on C level evidence [8]. The
current guidelines on carotid artery stent placement do not mention cilostazol as an alternative to clopidogrel [9]. In the coronary circulation, cilostazol reduced the incidence of restenosis after balloon angioplasty and bare metal stent placement compared with aspirin and
clopidogrel or ticlopidine [10–12]. Similarly, the combination of cilostazol and aspirin had
lower rates of restenosis following carotid artery stent placement compared with aspirin and
clopidogrel or ticlopidine in an observational study [13]. We performed a phase I open-label,
nonrandomized two-center prospective study, to determine the safety of 1-month treatment
with aspirin (325 mg/day) and cilostazol (200 mg/day) following extracranial stent placement.

Methods
We conducted a phase I open-label, nonrandomized two-center (Hennepin County Medical Center,
Minneapolis, MN and University of Minnesota Medical Center, Minneapolis, MN) prospective study with the
approval of the institutional review board of both hospitals. All subjects signed an informed consent prior to
participating in the study. Each patient received aspirin (325 mg/day) and cilostazol (200 mg/day) for 3 days
before extracranial stent placement. The two antiplatelet agents were continued for 1 month postprocedure
and then aspirin (325 mg) daily monotherapy was continued thereafter. Study subjects were 18 years of age
or older, with a baseline modified Rankin score of 0–2, who were scheduled to undergo extracranial internal
carotid artery stent placement with or without balloon angioplasty for symptomatic or asymptomatic carotid
artery stenosis. A distal embolic protection device was used with every stent placed. The internal carotid
stenosis had to be greater than 50% and less than or equal to 99% as measured by the North American Symptomatic Carotid Endarterectomy Trial (NASCET) [14]. Subjects who received a carotid stent had high surgical
risk features such as clinically significant cardiac disease (congestive heart failure, abnormal stress test, or
need for open-heart surgery), severe pulmonary disease, contralateral carotid occlusion, contralateral
laryngeal nerve palsy, previous radical neck surgery or radiation therapy to the neck, recurrent stenosis after
endarterectomy, and age greater than or equal to 80 years [15]. Also, stenting was preferred when there was
a high carotid artery bifurcation, at the level of the C2 vertebra and above.
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Subjects were excluded from participating in the study if they had a history of bleeding diathesis,
including disorders treated by warfarin therapy (however, those who had received warfarin but had stopped
taking the medication 3 days before the procedure and had an international normalized ratio less than 1.2
were eligible for inclusion). Similarly, subjects were excluded if they had severe hypertension (defined as
systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than100 mm Hg, despite
therapy), had a major surgery within the previous 6 weeks, or had a previous history of a hemorrhagic stroke.
Pregnant patients or women who were breast-feeding were excluded from the study. Subjects were also
excluded if they had gastrointestinal or genitourinary bleeding within the previous 30 days of treatment, had
platelets less than 30,000, and/or had congestive heart failure.
The primary efficacy end point was the 30-day composite occurrence of death, cerebral infarction, transient ischemic attack, and in-stent thrombosis requiring unplanned endovascular revascularization procedure.
The primary safety end point was bleeding. Bleeding complications were classified as major, moderate, or
minor according to criteria used by the Thrombolysis in Myocardial Infarction trial group [16]. Major bleeding
was defined as any intracranial hemorrhage or a decrease in hemoglobin level of less than 5 g/dL that resulted
in hemodynamic compromise requiring treatment. Moderate bleeding was defined by the need for transfusion.
Minor bleeding was defined as any decrease in hemoglobin level of 3 to 5 g/dL, not requiring transfusion or
causing hemodynamic compromise. The age of the subjects, gender, medical comorbidities, length of intensive
care stay (days), length of hospital stay (days), clinical indication for treatment, clinical presentation, and
location of carotid stenosis were abstracted from the electronic medical record. The intraprocedural details
regarding the stent deployed, whether pre- or post-balloon angioplasty was utilized as well as the balloon type,
the posttreatment stenosis, and complications were abstracted from the medical record. Similarly, the followup complications and 1-month modified Rankin scale scores were also documented for each patient.
Statistical Analysis
The data is presented in a descriptive presentation. The mean value with standard deviation (SD) was
presented for continuous variables including age and pre-stent and post-stent stenosis with or without
angioplasty. The total number of immediate procedure-related and postprocedure follow-up complications
were documented and counted. Postprocedure follow-up complications were defined as any complication
that occurred after the immediate procedure and within the follow-up time period.

Results

Twelve subjects (mean age ± SD, 66 ± 12 years; 9 men) were enrolled using the study
protocol and underwent internal carotid artery stent placement with or without angioplasty
with a distal embolic protection device. All the patients who received a carotid artery stent
had stenosis secondary to extracranial atherosclerotic disease; there were no carotid stents
placed for an arterial dissection. The procedure was performed in the right and left extracranial internal carotid arteries in 7 (58%) and 5 (42%) subjects, respectively. All the subjects
were treated using the Nitinol PRECISE® PRO RX® Stent system (Johnson and Johnson; New
Jersey) except for one patient who was treated with an Xpert stent (Abbott; Illinois, USA). The
decision to use the 4-mm Xpert stent (Abbott) was based on the size of the internal carotid
artery. The pre-stent percent stenosis and post-stent percent stenosis represented as mean
± SD were 79 ± 10% and 9 ± 10%, respectively. Pre-stent angioplasty was used in 5 subjects.
Post-stent angioplasty was used in 5 subjects. There was one patient who received pre-angioplasty dilation of the stenotic lesion followed by post-stent angioplasty for further lesion
dilation. One patient had stent placement alone, without pre- or post-angioplasty (see
Table 2). Patients 3 and 6 represent the same patient but the extracranial carotid arteries
were treated at separate time points, respectively, and were treated as two subjects (see
Table 1). Other comorbidities among study subjects included: hypertension in 10 (83%),
hyperlipidemia in 9 (75%), atrial fibrillation in 2 (17%), diabetes mellitus in 5 (42%), history
of recent ischemic stroke and/or TIA in 7 (58%), congestive heart failure in 3 (25%), and
tobacco dependence in 4 (33%) subjects.
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Table 1. Baseline and angiographic characteristics of the study subjects recruited in the phase I trial
Patient

Age,
years/
sex

Clinical presentation

Cardiovascular risk factors

Lesion
site

Pretreatment
stenosis, %

1

63/M

1 month prior to stenting had
multiple MRI-proven subacute and
acute infarcts in right cerebral
hemisphere; refused CEA

DM type II, hypertension

Right ICA

90

2

60/M

Multiple spells of amaurosis fugax of
right eye

Occluded left ICA, HTN, HPLD, severe
COPD

Right ICA

75

3

56/M

Acute ischemic stroke with right-side
hemiparesis and dysarthria

Nine years prior had neck radiation for
Hodgkin’s lymphoma; HTN; tobacco
dependent

Left ICA

85

4

75/F

TIA: sensory alteration of the right
side of the body

HTN, A. Fib., CHF, DM type II, HLPD

Left ICA

80

5

50/M

Acute ischemic stroke with left sided
hemiparesis

HTN, HLPD

Right ICA

70

6

56/M

Asymptomatic

Acute ischemic stroke secondary to a
severe left ICA 85% stenosis 2 months
prior to stenting; 9 years prior had neck
radiation for Hodgkin’s lymphoma; HTN;
tobacco dependent

Right ICA

85

7**

63/F

TIA: left hand weakness a week prior
to stenting

A. Fib., HTN, CHF, DM type II

Right ICA

80

8**

72/M

Amaurosis fugax of the left eye

HTN, HLPD, coronary artery disease, DM
type II

Left ICA

60

9

91/F

TIA: intermittent word finding
difficulties

HTN, DM type II, ischemic stroke (2004);
coronary artery disease with CABG

Left ICA

75

10

57/M

Right corona radiata ischemic stroke
with left hemiparesis

HTN, DM type II

Left ICA

99

11

71/M

Asymptomatic

HTN, HPLD, right ICA stenosis treated
with carotid stent previously, CHF

Right ICA

80

12

81/M

Acute ischemic stroke with left arm
and leg hemiparesis

Had poor medical follow-up. Did not have
any prior medical history

Right ICA

70

Patients No. 3 and 6 represent the same patient treated at different time points. The 2 subjects with asterisks were not included in
the study analysis because they did not complete the study. A. Fib., atrial fibrillation; CABG, coronary artery bypass graft; CEA, carotid
endarterectomy; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; F, female; HLPD,
hyperlipidemia; HTN, hypertension; ICA, internal carotid artery; M, male; MRI, magnetic resonance imaging; TIA, transient ischemic
attack.

All of the study subjects who successfully followed the study protocol completed the study
without any change in their pre- and posttreatment modified Rankin score and did not experience any intracerebral hemorrhage, systemic bleeding complications, ischemic stroke, transient ischemic attack, or in-stent thrombosis at the 1-month and 3-month follow-up. Prior to
stent placement, one patient discontinued cilostazol after the first dose secondary to nonspecific dizziness. There was a protocol deviation in one patient due to concurrent use of enoxaparin (1 mg/kg twice daily) in addition to aspirin and cilostazol. The patient suffered a fatal
symptomatic intracerebral hemorrhage following successful stent placement on postprocedure day 1. A third patient was successfully enrolled in the study but the cilostazol was
discontinued by her cardiologist 5 days after the successful and uncomplicated stent placement.
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Table 2. Procedural information and clinical outcomes in study subjects
Patient

Angioplasty performed

Stent (type,
size)

Posttreatment
stenosis,
%

IntraPost
Bleeding compliprocedural
procedure cations, stroke, TIA, stroke
com-plication death
or in-stent thrombosis/
occlusion at 1 month
posttreatment

ICU/total
hospital
stay, days

1 month
modified
Rankin scale
score

1

Mavericka,
3 mm × 20 mm

Precise,
7 mm × 40 mm

20

0

0

0

1/1

0

2

Aviatora,
4 mm × 20 mm;
Aviatorb,
5 mm × 20 mm

Precise,
8 mm × 30 mm

10

0

0

0

1/1

0

3

Viatracb,
4 mm × 20 mm

Precise,
7 mm × 30 mm

10

0

0

0

2/9

0

4

Aviatora,
4.0 mm × 30 mm

Precise,
7 mm × 30 mm

25

0

0

0

1/1

0

5

Viatracb,
4.5 mm × 20 mm

Precise,
8 mm × 30 mm

0

0

0

0

1/3

2
(baseline)

6

Viatracb,
4 mm × 20 mm

Precise,
7 mm × 40 mm

20

0

0

0

1/1

0

7**

Viatraca,
4 mm × 30 mm

Precise,
7 mm × 30 mm

0

0

1

–

1/2

6

8**

None

Xpert,
4 mm × 20 mm

0

0

0

0

1/1

0

9

Aviatora,
4.5 mm × 15 mm

Precise,
7 mm × 40 mm

20

0

0

0

1/1

0

10

Mavericka,
3 mm × 20 mm

Precise,
7 mm × 30 mm

0

0

0

0

1/2

0

11

Aviatorb,
5 mm × 30 mm

Precise,
6 mm × 40 mm

0

0

0

0

1/1

0

12

Viatracb,
5 mm × 30 mm

Precise,
7 mm × 40 mm

0

0

0

0

1/7

1

The 2 subjects with asterisks were not included in the study analysis because they did not complete the study.
a Pre-stent balloon. b Post-stent balloon.

Discussion

Ischemic stroke can occur during or after extracranial internal carotid artery stent
placement in rates varying from 4 to 10% depending on patient characteristics due to thromboembolic complications [17]. Clopidogrel and aspirin are the most commonly utilized antiplatelet medications prescribed prior to and following extracranial internal carotid artery
stent placement to prevent in-stent thrombosis. This is the first phase I study in the United
States that demonstrated the feasibility of using cilostazol and aspirin dual antiplatelet
therapy to prevent in-stent thrombosis following internal carotid artery stenting. When
adhering to the treatment regiment, cilostazol and aspirin appeared to be a safe treatment
alternative to aspirin and clopidogrel, but such an observation requires further prospective
studies to demonstrate efficacy in prevention of ischemic events. There are few reports that
have examined the efficacy of dual antiplatelet treatment with aspirin and cilostazol specifically following carotid stent placement, with the majority of studies focusing on patients with
coronary artery disease who have coronary stents placed [18].
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Aspirin and clopidogrel have been demonstrated to be safe in the setting of extracranial
carotid artery stenting. The IDEALCAST (Investigation on Devices and Antiplatelet Therapy
for Carotid Artery Stenting) investigators conducted a multicenter prospective observational
study on the onset of vascular events after carotid artery stenting in an effort to find out the
efficacy and safety of carotid artery stenting in Japan and to investigate the effects of antiplatelet drugs administered before and after carotid artery stenting on efficacy and safety of
carotid artery stenting. A total of 949 patients with extracranial carotid artery stenosis were
enrolled and 934 had carotid artery stents placed with antiplatelet drugs and were followed
for 1 year. The primary end point (incidence of the first event of death, ischemic stroke,
hemorrhagic stroke, transient ischemic attack, myocardial infarction, or serious hemorrhage
within 1 year after enrollment) was observed in 69 patients (7.4%) within 30 days of
enrollment and in 40 patients (4.3%) between 31 days and 1 year after enrollment. The
choice of antiplatelet agents in the periprocedural period was up to the investigators. The
incidence of the first event for aspirin and cilostazol was significantly lower than that for
aspirin and clopidogrel (p = 0.01), aspirin and clopidogrel and cilostazol (p = 0.01), and antiplatelet monotherapy (p ˂ 0.01) [9].
One of the limitations of bare metal stent implantation is the restenosis secondary to
intimal hyperplasia within or adjacent to the stent [19, 20]. Cilostazol has been found to reduce
neointimal formation in balloon-injured rat carotid arteries and inhibits restenosis after percutaneous transluminal coronary angioplasty [21, 22]. Takayama et al. [13] performed a retrospective, multicenter trial of 62 carotid artery lesions in 60 patients, studying the restenosis
rate following carotid artery stenting with the carotid wall stent. There was a cilostazol (aspirin,
100 mg, and cilostazol, 200 mg; n = 30) and non-cilostazol group (aspirin, 100 mg, and clopidogrel, 75 mg [n = 29], or ticlopidine, 100 mg [n = 2] or 200 mg [n = 1]). The two antiplatelet
medications were given 1 week preoperatively and continued for at least 3 months postoperatively. The patients were followed at 3 and 6 months postoperatively with an angiographic
study. Takayama et al. [13] found that there were 5 cases of asymptomatic restenosis (8.3%) (4
were from the aspirin and clopidogrel group, and 1 was from the ticlopidine group) but none
in the cilostazol treatment group, and the difference was statistically significant (p = 0.0239).
This study was intended to demonstrate the safety and feasibility of the addition of cilostazol to aspirin prior to and following extracranial carotid artery stenting, but there are limitations. One limitation of the study is the small sample size and its open-label design. The
subjects were not randomized with a comparator group, and the results may not be representative of patients with characteristics different from the inclusion and exclusion criteria used.
Conclusion

The use of cilostazol and aspirin for internal carotid artery stent placement appears to be
safe, but protocol compliance needs to be emphasized. Further studies are required to analyze
the effectiveness and role of cilostazol in neurointerventional procedures.
Statement of Ethics
All the research meets the ethical guidelines, including adherence to the legal requirements of the study
country.
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